Translational study searching for synergy between glycopyrronium and indacaterol

Mario Cazzola, Luigino Calzetta, Andrea Segreti, Francesco Facciolo, Paola Rogliani, Maria Gabriella Matera

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

We aimed to explore whether the acute bronchodilation induced by indacaterol 150 μg and glycopyrronium bromide 50 μg is additive or synergistic with respect to monocomponents by testing the type of effect ex vivo on isolated human bronchi and then in vivo in COPD patients. Both indacaterol and glycopyrronium caused a concentration-dependent relaxation of human isolated bronchial tissues sub-maximally pre-contracted with acetylcholine; glycopyrronium was significantly more potent than indacaterol. The analysis of data using the Bliss Independence (BI) criterion indicated that glycopyrronium plus indacaterol produced an additive interaction at the isoeffective concentrations inducing EC20 and a significant synergistic relaxant effect at isoeffective concentrations inducing EC30. In COPD patients, the inhalation of indacaterol and glycopyrronium in combination significantly anticipated at 15 min post-administration the mean peak of bronchodilatory effect compared to the two drugs administered alone. The study of interaction between indacaterol and glycopyrronium by BI analysis evidenced an additive effect for FEV1 between 5 min and 180 min post-inhalation, with synergistic interaction at 15 min post-administration, compared to the bronchodilation induced by these drugs administered alone. This study suggests that the combination ensures a broncholytic effect that is greater than that induced by the single monocomponents.

Original languageEnglish
Pages (from-to)175-181
Number of pages7
JournalCOPD: Journal of Chronic Obstructive Pulmonary Disease
Volume12
Issue number2
DOIs
Publication statusPublished - Apr 14 2015

Fingerprint

Chronic Obstructive Pulmonary Disease
Inhalation
Glycopyrrolate
Bronchodilator Agents
Bronchi
Pharmaceutical Preparations
Acetylcholine
indacaterol

Keywords

  • Combination therapy
  • Glycopyrronium
  • Indacaterol
  • Synergy
  • Traslational evaluation

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Translational study searching for synergy between glycopyrronium and indacaterol. / Cazzola, Mario; Calzetta, Luigino; Segreti, Andrea; Facciolo, Francesco; Rogliani, Paola; Matera, Maria Gabriella.

In: COPD: Journal of Chronic Obstructive Pulmonary Disease, Vol. 12, No. 2, 14.04.2015, p. 175-181.

Research output: Contribution to journalArticle

Cazzola, Mario ; Calzetta, Luigino ; Segreti, Andrea ; Facciolo, Francesco ; Rogliani, Paola ; Matera, Maria Gabriella. / Translational study searching for synergy between glycopyrronium and indacaterol. In: COPD: Journal of Chronic Obstructive Pulmonary Disease. 2015 ; Vol. 12, No. 2. pp. 175-181.
@article{9a6025addd154b28aeb5b401bf168b70,
title = "Translational study searching for synergy between glycopyrronium and indacaterol",
abstract = "We aimed to explore whether the acute bronchodilation induced by indacaterol 150 μg and glycopyrronium bromide 50 μg is additive or synergistic with respect to monocomponents by testing the type of effect ex vivo on isolated human bronchi and then in vivo in COPD patients. Both indacaterol and glycopyrronium caused a concentration-dependent relaxation of human isolated bronchial tissues sub-maximally pre-contracted with acetylcholine; glycopyrronium was significantly more potent than indacaterol. The analysis of data using the Bliss Independence (BI) criterion indicated that glycopyrronium plus indacaterol produced an additive interaction at the isoeffective concentrations inducing EC20 and a significant synergistic relaxant effect at isoeffective concentrations inducing EC30. In COPD patients, the inhalation of indacaterol and glycopyrronium in combination significantly anticipated at 15 min post-administration the mean peak of bronchodilatory effect compared to the two drugs administered alone. The study of interaction between indacaterol and glycopyrronium by BI analysis evidenced an additive effect for FEV1 between 5 min and 180 min post-inhalation, with synergistic interaction at 15 min post-administration, compared to the bronchodilation induced by these drugs administered alone. This study suggests that the combination ensures a broncholytic effect that is greater than that induced by the single monocomponents.",
keywords = "Combination therapy, Glycopyrronium, Indacaterol, Synergy, Traslational evaluation",
author = "Mario Cazzola and Luigino Calzetta and Andrea Segreti and Francesco Facciolo and Paola Rogliani and Matera, {Maria Gabriella}",
year = "2015",
month = "4",
day = "14",
doi = "10.3109/15412555.2014.922172",
language = "English",
volume = "12",
pages = "175--181",
journal = "COPD: Journal of Chronic Obstructive Pulmonary Disease",
issn = "1541-2555",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Translational study searching for synergy between glycopyrronium and indacaterol

AU - Cazzola, Mario

AU - Calzetta, Luigino

AU - Segreti, Andrea

AU - Facciolo, Francesco

AU - Rogliani, Paola

AU - Matera, Maria Gabriella

PY - 2015/4/14

Y1 - 2015/4/14

N2 - We aimed to explore whether the acute bronchodilation induced by indacaterol 150 μg and glycopyrronium bromide 50 μg is additive or synergistic with respect to monocomponents by testing the type of effect ex vivo on isolated human bronchi and then in vivo in COPD patients. Both indacaterol and glycopyrronium caused a concentration-dependent relaxation of human isolated bronchial tissues sub-maximally pre-contracted with acetylcholine; glycopyrronium was significantly more potent than indacaterol. The analysis of data using the Bliss Independence (BI) criterion indicated that glycopyrronium plus indacaterol produced an additive interaction at the isoeffective concentrations inducing EC20 and a significant synergistic relaxant effect at isoeffective concentrations inducing EC30. In COPD patients, the inhalation of indacaterol and glycopyrronium in combination significantly anticipated at 15 min post-administration the mean peak of bronchodilatory effect compared to the two drugs administered alone. The study of interaction between indacaterol and glycopyrronium by BI analysis evidenced an additive effect for FEV1 between 5 min and 180 min post-inhalation, with synergistic interaction at 15 min post-administration, compared to the bronchodilation induced by these drugs administered alone. This study suggests that the combination ensures a broncholytic effect that is greater than that induced by the single monocomponents.

AB - We aimed to explore whether the acute bronchodilation induced by indacaterol 150 μg and glycopyrronium bromide 50 μg is additive or synergistic with respect to monocomponents by testing the type of effect ex vivo on isolated human bronchi and then in vivo in COPD patients. Both indacaterol and glycopyrronium caused a concentration-dependent relaxation of human isolated bronchial tissues sub-maximally pre-contracted with acetylcholine; glycopyrronium was significantly more potent than indacaterol. The analysis of data using the Bliss Independence (BI) criterion indicated that glycopyrronium plus indacaterol produced an additive interaction at the isoeffective concentrations inducing EC20 and a significant synergistic relaxant effect at isoeffective concentrations inducing EC30. In COPD patients, the inhalation of indacaterol and glycopyrronium in combination significantly anticipated at 15 min post-administration the mean peak of bronchodilatory effect compared to the two drugs administered alone. The study of interaction between indacaterol and glycopyrronium by BI analysis evidenced an additive effect for FEV1 between 5 min and 180 min post-inhalation, with synergistic interaction at 15 min post-administration, compared to the bronchodilation induced by these drugs administered alone. This study suggests that the combination ensures a broncholytic effect that is greater than that induced by the single monocomponents.

KW - Combination therapy

KW - Glycopyrronium

KW - Indacaterol

KW - Synergy

KW - Traslational evaluation

UR - http://www.scopus.com/inward/record.url?scp=84928945280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928945280&partnerID=8YFLogxK

U2 - 10.3109/15412555.2014.922172

DO - 10.3109/15412555.2014.922172

M3 - Article

C2 - 25222881

AN - SCOPUS:84928945280

VL - 12

SP - 175

EP - 181

JO - COPD: Journal of Chronic Obstructive Pulmonary Disease

JF - COPD: Journal of Chronic Obstructive Pulmonary Disease

SN - 1541-2555

IS - 2

ER -